[go: up one dir, main page]

EA201790882A1 - Способы и композиции для терапии рака печени - Google Patents

Способы и композиции для терапии рака печени

Info

Publication number
EA201790882A1
EA201790882A1 EA201790882A EA201790882A EA201790882A1 EA 201790882 A1 EA201790882 A1 EA 201790882A1 EA 201790882 A EA201790882 A EA 201790882A EA 201790882 A EA201790882 A EA 201790882A EA 201790882 A1 EA201790882 A1 EA 201790882A1
Authority
EA
Eurasian Patent Office
Prior art keywords
liver cancer
methods
compositions
cancer therapy
progastrin
Prior art date
Application number
EA201790882A
Other languages
English (en)
Inventor
Лейла Уу
Анн-Софи Дюме
Доминик Жубер
Фредерик Олланд
Original Assignee
Ле Лаборатуар Сервье
Инститю Насьональ Де Ля Сент Э Де Ля Решерш Медисаль (Инсерм)
Сантр Насьональ Де Ля Решерш Сьентифик (Снрс)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ле Лаборатуар Сервье, Инститю Насьональ Де Ля Сент Э Де Ля Решерш Медисаль (Инсерм), Сантр Насьональ Де Ля Решерш Сьентифик (Снрс) filed Critical Ле Лаборатуар Сервье
Publication of EA201790882A1 publication Critical patent/EA201790882A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящая заявка обеспечивает способы лечения рака печени и предотвращения рецидива рака печени с помощью антипрогастриновых антител, способы мониторинга эффективности лечения рака печени при использовании антипрогастриновой терапии и композиции, которые применяются для этого.
EA201790882A 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени EA201790882A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36785110P 2010-07-26 2010-07-26
US201161476204P 2011-04-15 2011-04-15

Publications (1)

Publication Number Publication Date
EA201790882A1 true EA201790882A1 (ru) 2017-08-31

Family

ID=45493809

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201300171A EA028515B1 (ru) 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени
EA201790882A EA201790882A1 (ru) 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201300171A EA028515B1 (ru) 2010-07-26 2011-07-22 Способы и композиции для терапии рака печени

Country Status (16)

Country Link
US (1) US10533050B2 (ru)
EP (1) EP2598531B1 (ru)
JP (1) JP5726305B2 (ru)
KR (1) KR101576174B1 (ru)
CN (1) CN103261224B (ru)
AR (1) AR082340A1 (ru)
AU (1) AU2011284908B2 (ru)
BR (1) BR112013002012A2 (ru)
CA (1) CA2806157C (ru)
EA (2) EA028515B1 (ru)
ES (1) ES2871092T3 (ru)
NZ (1) NZ606195A (ru)
PL (1) PL2598531T3 (ru)
SG (2) SG10201703556YA (ru)
WO (1) WO2012013609A1 (ru)
ZA (1) ZA201300567B (ru)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101638490B1 (ko) 2008-08-05 2016-07-11 도레이 카부시키가이샤 암의 치료 및 예방용 의약 조성물
DK2325648T3 (da) 2008-08-05 2014-07-28 Toray Industries Fremgangsmåde til detektering af cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
RU2603742C2 (ru) 2010-02-04 2016-11-27 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
MX351682B (es) 2011-08-04 2017-10-25 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EP2741085B1 (en) 2011-08-04 2017-04-05 Toray Industries, Inc. Method for detecting pancreatic cancer
BR112014002619A2 (pt) 2011-08-04 2018-10-09 Toray Industries, Inc composição farmacêutica e método de tratamento e/ou prevenção de câncer pancreático e combinação farmacêutica
HUE046788T2 (hu) 2012-02-21 2020-03-30 Toray Industries Gyógyászati készítmény rák kezelésére és/vagy megelõzésére
DK2818483T3 (en) 2012-02-21 2017-10-23 Toray Industries Medical composition for the treatment and / or prevention of cancer
KR102009236B1 (ko) 2012-02-21 2019-08-09 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
CA2864864C (en) 2012-02-21 2020-05-12 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
WO2013147176A1 (ja) 2012-03-30 2013-10-03 東レ株式会社 胆嚢癌の治療及び／又は予防用医薬組成物
EP2876447B1 (en) 2012-07-19 2019-11-20 Toray Industries, Inc. Method for detecting cancer
CN104471403B (zh) 2012-07-19 2017-03-01 东丽株式会社 癌的检测方法
PT3031826T (pt) 2013-08-09 2019-01-18 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro
MX2017003049A (es) * 2014-09-10 2017-05-23 Double Bond Pharmaceuticals Ab Administracion dirigida de farmacos hidrofilicos.
EP3023884A1 (en) * 2014-11-21 2016-05-25 Thomson Licensing Method and apparatus for generating fingerprint of an audio signal
BR112018013271A2 (pt) 2015-12-31 2018-12-11 Progastrine Et Cancers S A R L composições e métodos para detectar e tratar câncer de ovário
AU2017204686B2 (en) 2015-12-31 2020-04-30 Progastrine Et Cancers S.À R.L. Compositions and methods for detecting and treating esophageal cancer
CA3009740A1 (en) 2015-12-31 2017-07-06 Progastrine Et Cancers S.A R.L. Compositions and methods for detecting and treating gastric cancer
CA3009768A1 (en) 2015-12-31 2017-07-06 Syncerus S.A R.L. Compositions and methods for assessing the risk of cancer occurrence
KR102351556B1 (ko) 2017-03-30 2022-01-14 프로가스트린 에 캔서스 에스.에이 알.엘. 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
JP7251541B2 (ja) 2017-03-30 2023-04-04 イー、シー、エス、プロガストリン、エス、エー 肺癌検出のための組成物と方法
TWI763956B (zh) * 2017-12-05 2022-05-11 盧森堡商前胃泌激素及癌症有限公司 治療癌症的抗前胃泌激素抗體與免疫療法之組合療法
JP7338128B2 (ja) 2017-12-08 2023-09-05 イー、シー、エス、ビオトラッカー、エス、エー、アール、エル 癌診断における放射性標識プロガストリン
TW201940881A (zh) 2018-01-26 2019-10-16 瑞士商Ｅｃｓ前胃泌激素公司 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術
US20200400675A1 (en) * 2018-02-27 2020-12-24 Ecs-Progastrin Sa Progastrin as a biomarker for immunotherapy
WO2021067775A1 (en) * 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anto-connexin antibody formulations
WO2025031290A1 (zh) * 2023-08-04 2025-02-13 信达生物制药(苏州)有限公司 抗ox40l抗体以及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
EP1077721B8 (en) * 1998-05-15 2007-06-20 Receptor Biologix, Inc. Prevention and treatment of hypergastrinemia
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
AU2004247069A1 (en) * 2003-06-02 2004-12-23 Alexion Pharmaceuticals, Inc. Cell surface protein associated with human chronic lymphocytic leukemia
US8158128B2 (en) * 2004-09-22 2012-04-17 Cancer Advances, Inc. Monoclonal antibodies to progastrin
JP5651331B2 (ja) * 2006-05-22 2015-01-14 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 結腸直腸癌の治療におけるプロガストリン阻害剤
WO2008076454A1 (en) 2006-12-19 2008-06-26 The Board Of Regents Of The University Of Texas System Immunogenic compositions comprising progastrin and uses thereof
PT2488551T (pt) * 2009-10-16 2018-10-31 Inst Nat Sante Rech Med Anticorpos monoclonais contra a progastrina e suas utilizações
US8900588B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Methods for treating breast cancer
US9217032B2 (en) * 2010-01-08 2015-12-22 Les Laboratoires Servier Methods for treating colorectal cancer
US8900817B2 (en) * 2010-01-08 2014-12-02 Les Laboratories Servier Progastrin and liver pathologies
US20150071912A1 (en) * 2010-03-24 2015-03-12 Centre National De La Recherche Scientifique (Cnrs) Prophylaxis of colorectal and gastrointestinal cancer

Also Published As

Publication number Publication date
AU2011284908A1 (en) 2013-02-07
CN103261224B (zh) 2015-10-07
AR082340A1 (es) 2012-11-28
EA028515B1 (ru) 2017-11-30
PL2598531T3 (pl) 2021-08-30
US20120020961A1 (en) 2012-01-26
ZA201300567B (en) 2014-03-26
SG10201703556YA (en) 2017-06-29
WO2012013609A1 (en) 2012-02-02
EA201300171A1 (ru) 2013-07-30
EP2598531B1 (en) 2020-12-30
KR101576174B1 (ko) 2015-12-09
CA2806157A1 (en) 2012-02-02
CA2806157C (en) 2016-11-22
US10533050B2 (en) 2020-01-14
JP2013533277A (ja) 2013-08-22
AU2011284908B2 (en) 2015-05-21
EP2598531A1 (en) 2013-06-05
KR20130083438A (ko) 2013-07-22
CN103261224A (zh) 2013-08-21
NZ606195A (en) 2015-02-27
SG187544A1 (en) 2013-03-28
ES2871092T3 (es) 2021-10-28
BR112013002012A2 (pt) 2019-08-27
JP5726305B2 (ja) 2015-05-27

Similar Documents

Publication Publication Date Title
EA201790882A1 (ru) Способы и композиции для терапии рака печени
EA201890754A1 (ru) Соединения и способы их применения
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201591340A1 (ru) Модулятор андрогенного рецептора и его применения
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201590997A1 (ru) Соединения и способы их применения
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
EA201201000A1 (ru) Способы лечения колоректального рака
EA201490778A1 (ru) АНТИТЕЛА ПРОТИВ HtrA1 И СПОСОБЫ ПРИМЕНЕНИЯ
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
EA201290919A1 (ru) Индазольные соединения и их применение
EA201390145A1 (ru) Конъюгаты, частицы, композиции и связанные с ними способы
EA201690306A1 (ru) Ингибиторы ido
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
EA201591599A1 (ru) Ингибиторы ido
EA201190224A1 (ru) Ингибиторы гепатита c, содержащие конденсированные кольца
EA201170349A1 (ru) Модуляторы mif
EA201291194A1 (ru) Индолы
BR112013005116A2 (pt) moduladores e métodos de uso
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201171396A1 (ru) Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата